[8-K] Jasper Therapeutics, Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Redmile Group, LLC, Jeremy C. Green and RedCo II Master Fund, L.P. have filed Amendment No. 9 to their Schedule 13D on Fate Therapeutics, Inc. (NASDAQ: FATE). The filing, triggered by an event dated 07 July 2025, updates the group鈥檚 ownership disclosure and key blocking provisions.

Aggregate beneficial ownership: 17,941,579 common shares (direct and deemed) representing 14.9 % of FATE鈥檚 outstanding common stock (114,633,022 shares as of 6 May 2025).
Key holder detail: RedCo II Master Fund holds 13,479,013 shares (11.3 %). All shares are subject to shared voting and dispositive power; no reporting person has sole power.
Warrants & preferred stock: 鈥� Pre-Funded Warrants covering 3,691,324 shares (exercise price $0.001) 鈥� Class A Preferred Stock convertible 1-for-5 into up to 810,065 shares (RedCo II) and additional preferred shares across other Redmile funds.
Both instruments are governed by 14.99 % beneficial-ownership blockers.
Change in blocker threshold: On 1 July 2025 Redmile elected to raise the 鈥淢aximum Percentage鈥� under the Warrant Beneficial Ownership Blocker from 9.99 % to 14.99 % (effective 61 days later). This allows the group to exercise additional warrants and approach the new 14.99 % cap without breaching Section 13(d) limits.
Funding source: Working capital of various Redmile-managed private investment funds (no external financing disclosed).
Historical context: This is the ninth amendment to an initial 13D filed in 2018, reflecting the evolution of Redmile鈥檚 position and security mix (common, warrants, preferred, options, RSUs).

The amendment does not announce new purchases or sales but formalises the larger ownership cap, clarifies the composition of the beneficial stake, and reiterates blocker mechanics designed to limit ownership to 14.99 % of outstanding commons.

Redmile Group, LLC, Jeremy C. Green e RedCo II Master Fund, L.P. hanno presentato l'Emendamento n. 9 al loro Schedule 13D su Fate Therapeutics, Inc. (NASDAQ: FATE). La comunicazione, scaturita da un evento del 7 luglio 2025, aggiorna la dichiarazione di propriet脿 del gruppo e le principali disposizioni di blocco.

Propriet脿 beneficiaria aggregata: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale sociale ordinario di FATE (114.633.022 azioni al 6 maggio 2025).
Dettaglio dei principali detentori: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri condivisi di voto e disposizione; nessun soggetto segnalante ha potere esclusivo.
Warrant e azioni privilegiate: 鈥� Warrant prefinanziati che coprono 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1 a 5 fino a un massimo di 810.065 azioni (RedCo II) e ulteriori azioni privilegiate in altri fondi gestiti da Redmile.
Entrambi gli strumenti sono soggetti a blocchi di propriet脿 beneficiaria del 14,99 %.
Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha deciso di aumentare la 鈥淧ercentuale Massima鈥� prevista dal blocco di propriet脿 beneficiaria dei warrant dal 9,99 % al 14,99 % (efficace dopo 61 giorni). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
Fonte di finanziamento: Capitale circolante di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
Contesto storico: Questo 猫 il nono emendamento a un 13D iniziale depositato nel 2018, che riflette l'evoluzione della posizione e della composizione degli strumenti di Redmile (azioni ordinarie, warrant, azioni privilegiate, opzioni, RSU).

L'emendamento non annuncia nuovi acquisti o vendite ma formalizza il limite superiore di propriet脿, chiarisce la composizione della partecipazione beneficiaria e ribadisce i meccanismi di blocco progettati per limitare la propriet脿 al 14,99 % delle azioni ordinarie in circolazione.

Redmile Group, LLC, Jeremy C. Green y RedCo II Master Fund, L.P. han presentado la Enmienda N潞 9 a su Schedule 13D sobre Fate Therapeutics, Inc. (NASDAQ: FATE). La presentaci贸n, originada por un evento fechado el 7 de julio de 2025, actualiza la divulgaci贸n de propiedad del grupo y las principales disposiciones de bloqueo.

Propiedad beneficiaria agregada: 17.941.579 acciones ordinarias (directas y consideradas) que representan el 14,9 % del capital social ordinario en circulaci贸n de FATE (114.633.022 acciones al 6 de mayo de 2025).
Detalle del titular clave: RedCo II Master Fund posee 13.479.013 acciones (11,3 %). Todas las acciones est谩n sujetas a poder compartido de voto y disposici贸n; ninguna persona reportante tiene poder exclusivo.
Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3.691.324 acciones (precio de ejercicio $0,001) 鈥� Acciones preferentes Clase A convertibles 1 por 5 hasta un m谩ximo de 810.065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
Ambos instrumentos est谩n regulados por bloqueos de propiedad beneficiaria del 14,99 %.
Cambio en el umbral del bloqueo: El 1 de julio de 2025 Redmile decidi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueo de Propiedad Beneficiaria de Warrants del 9,99 % al 14,99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14,99 % sin violar los l铆mites de la Secci贸n 13(d).
Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privados gestionados por Redmile (no se declar贸 financiamiento externo).
Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n y la mezcla de valores de Redmile (ordinarias, warrants, preferentes, opciones, RSU).

La enmienda no anuncia nuevas compras o ventas, pero formaliza el l铆mite mayor de propiedad, aclara la composici贸n de la participaci贸n beneficiaria y reitera los mecanismos de bloqueo dise帽ados para limitar la propiedad al 14,99 % de las acciones ordinarias en circulaci贸n.

Redmile Group, LLC, Jeremy C. Green 氚� RedCo II Master Fund, L.P.臧€ Fate Therapeutics, Inc. (NASDAQ: FATE)鞐� 雽€頃� Schedule 13D 靾橃爼鞎� 9順鸽ゼ鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 7鞚� 氚滌儩頃� 靷贝鞐� 鞚橅暣齑夒皽霅� 鞚� 鞝滌稖鞚€ 攴鸽９鞚� 靻岇湢甓� 瓿店皽氚� 欤检殧彀嫧臁绊暛鞚� 鞐呺嵃鞚错姼頃╇媹雼�.

齑� 鞁れ 靻岇湢甓�: 17,941,579欤�(歆侅爲氚� 臧勳＜)搿� FATE鞚� 氚滍枆氤错喌欤�(2025雲� 5鞗� 6鞚� 旮办 114,633,022欤�)鞚� 14.9 %毳� 彀頃╇媹雼�.
欤检殧氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3%)毳� 氤挫湢頃橁碃鞛堨姷雼堧嫟. 氇摖欤检嫕鞚€ 瓿惦彊韴憸氚� 觳橂秳甓岉暅鞚� 鞝侅毄霅橂┌, 雼弲甓岉暅鞚� 臧€歆� 氤搓碃鞛愲姅鞐嗢姷雼堧嫟.
鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓臧€瓴� $0.001鞚� 3,691,324欤检棎雽€頃� 靹犽偐鞗岆煱韸� 鈥� 斓滊寑 810,065欤缄箤歆€ 1雽€ 5 鞝勴櫂臧€電ロ暅 A霌标笁鞖办劆欤�(RedCo II) 氚� 旮绊儉 Redmile 韼€霌滌棎攵勴彫霅� 於旉皜鞖办劆欤�.
霊� 旮堨湹靸來拡氇憪 14.99% 鞁れ 靻岇湢甓� 彀嫧攴滌爼鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟.
彀嫧鞛勱硠臧� 氤€瓴�: 2025雲� 7鞗� 1鞚�, Redmile鞚€ 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办潣鈥滌禍雽€ 牍勳湪鈥濎潉 9.99%鞐愳劀 14.99%搿� 靸來枼臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�, 鞚措姅 61鞚� 頉勳棎氚滍毃霅╇媹雼�. 鞚措ゼ韱淀暣攴鸽９鞚€ 於旉皜鞗岆煱韸鸽ゼ頄夓偓頃橁碃靸堧鞖� 14.99% 頃滊弰鞐� 鞝戧芳頃� 靾� 鞛堨溂雮� 13(d) 臁绊暛頃滊弰電� 齑堦臣頃橃 鞎婌姷雼堧嫟.
鞛愱笀於滌矘: Redmile鞚� 甏€毽晿電� 鞐煬靷 韴瀽韼€霌滌潣鞖挫爠鞛愲掣(鞕鸽秬鞛愱笀臁半嫭鞐嗢潓).
鞐偓鞝� 氚瓣步: 鞚措姅 2018雲勳棎鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 歆€攵� 氚� 歃濌秾甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤€頇旊ゼ氚橃榿頃╇媹雼�.

鞚措矆靾橃爼鞎堨潃靸堧鞖� 毵れ垬雮� 毵る弰毳� 氚滍憸頃橃 鞎婌溂氅�, 雿� 雴掛潃靻岇湢頃滊弰毳� 瓿奠嫕頇旐晿瓿�, 鞁れ 歆€攵� 甑劚鞚� 氇呿檿頌� 頃橂┌, 氚滍枆氤错喌欤检潣 14.99% 頃滊弰搿� 靻岇湢甓岇潉鞝滍暅頃橁赴鞙勴暅彀嫧氅旍护雼堨鞚� 鞛檿鞚疙暕雼堧嫟.

Redmile Group, LLC, Jeremy C. Green et RedCo II Master Fund, L.P. ont d茅pos茅 l'Amendement n掳 9 脿 leur Schedule 13D concernant Fate Therapeutics, Inc. (NASDAQ : FATE). Ce d茅p么t, d茅clench茅 par un 茅v茅nement dat茅 du 7 juillet 2025, met 脿 jour la divulgation de la propri茅t茅 du groupe ainsi que les principales dispositions de blocage.

Propri茅t茅 b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social ordinaire en circulation de FATE (114 633 022 actions au 6 mai 2025).
D茅tail des principaux d茅tenteurs : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir de vote et de disposition partag茅 ; aucune personne d茅clarant n鈥檃 de pouvoir exclusif.
Warrants et actions privil茅gi茅es : 鈥� Warrants pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) ainsi que des actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
Les deux instruments sont soumis 脿 des m茅canismes de blocage de propri茅t茅 b茅n茅ficiaire 脿 14,99 %.
Changement du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 Pourcentage Maximum 禄 sous le m茅canisme de blocage de propri茅t茅 b茅n茅ficiaire des warrants de 9,99 % 脿 14,99 % (effectif 61 jours plus tard). Cela permet au groupe d鈥檈xercer des warrants suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la Section 13(d).
Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position et de la composition des titres de Redmile (ordinaires, warrants, privil茅gi茅es, options, RSU).

L鈥檃mendement n鈥檃nnonce pas de nouveaux achats ou ventes mais formalise le plafond de propri茅t茅 plus 茅lev茅, clarifie la composition de la participation b茅n茅ficiaire et r茅affirme les m茅canismes de blocage destin茅s 脿 limiter la propri茅t茅脿 14,99 % des actions ordinaires en circulation.

Redmile Group, LLC, Jeremy C. Green und RedCo II Master Fund, L.P. haben die 脛nderung Nr. 9 zu ihrem Schedule 13D bez眉glich Fate Therapeutics, Inc. (NASDAQ: FATE) eingereicht. Die Einreichung, ausgel枚st durch ein Ereignis vom 7. Juli 2025, aktualisiert die Offenlegung der Eigentumsverh盲ltnisse der Gruppe sowie wichtige Blockierungsbestimmungen.

骋别蝉补尘迟苍耻迟锄苍颈别脽别谤-贰颈驳别苍迟耻尘: 17.941.579 Stammaktien (direkt und als gehalten betrachtet), was 14,9 % des ausstehenden Stammkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
Details zu Hauptanteilseignern: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen geteilter Stimm- und Verf眉gungsgewalt; keine meldepflichtige Person hat Alleinmacht.
Warrants & Vorzugsaktien: 鈥� Vorgezahlte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, konvertierbar 1 zu 5 in bis zu 810.065 Aktien (RedCo II) sowie weitere Vorzugsaktien in anderen Redmile-Fonds.
Beide Instrumente unterliegen 14,99 % Nutznie脽er-Eigentums-Blockern.
脛nderung der Blockierschwelle: Am 1. Juli 2025 entschied Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant-Nutznie脽er-Eigentums-Blocker von 9,99 % auf 14,99 % anzuheben (wirksam 61 Tage sp盲ter). Dies erm枚glicht der Gruppe, zus盲tzliche Warrants auszu眉ben und sich der neuen 14,99 %-Grenze zu n盲hern, ohne die Sektion 13(d)-Grenzen zu 眉berschreiten.
Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglich 2018 eingereichten 13D, die die Entwicklung von Redmiles Position und Wertpapiermix (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs) widerspiegelt.

Die 脛nderung k眉ndigt keine neuen K盲ufe oder Verk盲ufe an, formalisiert jedoch die h枚here Eigentumsgrenze, kl盲rt die Zusammensetzung des Beg眉nstigtenanteils und bekr盲ftigt die Blockierungsmechanismen, die darauf ausgelegt sind, das Eigentum auf 14,99 % der ausstehenden Stammaktien zu begrenzen.

Insights

TL;DR 鈥� Redmile lifts ownership cap to 14.99 %, reaffirming a large strategic stake without immediate cash impact.

The filing signals continued commitment from a specialist biotech investor. Moving the blocker from 9.99 % to 14.99 % allows Redmile to convert/exercise up to roughly 4.9 million additional shares (options, warrants, preferred) over time. Because the warrants are pre-funded at $0.001, Fate receives negligible incremental cash; the principal impact is potential dilution and voting concentration. No new purchases are disclosed, so near-term float dynamics remain unchanged. Overall, this is structurally important but not fundamentally value-changing in the short term.

TL;DR 鈥� Ownership concentration rises; possible governance influence, but still below 15 % control threshold.

Redmile now controls nearly 15 % of FATE鈥檚 voting power, positioning it as the company鈥檚 leading shareholder. While the firm disclaims control intent, a stake of this size affords meaningful influence over board matters and strategic direction, especially in biotech where floats are limited. The blocker election is a permissible mechanism under SEC rules, but shareholders should watch for future activism or alignment proposals. Because the cap remains below 15 %, poison-pill or change-of-control triggers are unlikely to activate.

Propriet脿 beneficiaria aggregata: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale sociale ordinario di FATE (114.633.022 azioni al 6 maggio 2025).
Dettaglio dei principali detentori: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri condivisi di voto e disposizione; nessun soggetto segnalante ha potere esclusivo.
Warrant e azioni privilegiate: 鈥� Warrant prefinanziati che coprono 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1 a 5 fino a un massimo di 810.065 azioni (RedCo II) e ulteriori azioni privilegiate in altri fondi gestiti da Redmile.
Entrambi gli strumenti sono soggetti a blocchi di propriet脿 beneficiaria del 14,99 %.
Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha deciso di aumentare la 鈥淧ercentuale Massima鈥� prevista dal blocco di propriet脿 beneficiaria dei warrant dal 9,99 % al 14,99 % (efficace dopo 61 giorni). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
Fonte di finanziamento: Capitale circolante di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
Contesto storico: Questo 猫 il nono emendamento a un 13D iniziale depositato nel 2018, che riflette l'evoluzione della posizione e della composizione degli strumenti di Redmile (azioni ordinarie, warrant, azioni privilegiate, opzioni, RSU).

Propiedad beneficiaria agregada: 17.941.579 acciones ordinarias (directas y consideradas) que representan el 14,9 % del capital social ordinario en circulaci贸n de FATE (114.633.022 acciones al 6 de mayo de 2025).
Detalle del titular clave: RedCo II Master Fund posee 13.479.013 acciones (11,3 %). Todas las acciones est谩n sujetas a poder compartido de voto y disposici贸n; ninguna persona reportante tiene poder exclusivo.
Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3.691.324 acciones (precio de ejercicio $0,001) 鈥� Acciones preferentes Clase A convertibles 1 por 5 hasta un m谩ximo de 810.065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
Ambos instrumentos est谩n regulados por bloqueos de propiedad beneficiaria del 14,99 %.
Cambio en el umbral del bloqueo: El 1 de julio de 2025 Redmile decidi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueo de Propiedad Beneficiaria de Warrants del 9,99 % al 14,99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14,99 % sin violar los l铆mites de la Secci贸n 13(d).
Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privados gestionados por Redmile (no se declar贸 financiamiento externo).
Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n y la mezcla de valores de Redmile (ordinarias, warrants, preferentes, opciones, RSU).

齑� 鞁れ 靻岇湢甓�: 17,941,579欤�(歆侅爲氚� 臧勳＜)搿� FATE鞚� 氚滍枆氤错喌欤�(2025雲� 5鞗� 6鞚� 旮办 114,633,022欤�)鞚� 14.9 %毳� 彀頃╇媹雼�.
欤检殧氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3%)毳� 氤挫湢頃橁碃鞛堨姷雼堧嫟. 氇摖欤检嫕鞚€ 瓿惦彊韴憸氚� 觳橂秳甓岉暅鞚� 鞝侅毄霅橂┌, 雼弲甓岉暅鞚� 臧€歆� 氤搓碃鞛愲姅鞐嗢姷雼堧嫟.
鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓臧€瓴� $0.001鞚� 3,691,324欤检棎雽€頃� 靹犽偐鞗岆煱韸� 鈥� 斓滊寑 810,065欤缄箤歆€ 1雽€ 5 鞝勴櫂臧€電ロ暅 A霌标笁鞖办劆欤�(RedCo II) 氚� 旮绊儉 Redmile 韼€霌滌棎攵勴彫霅� 於旉皜鞖办劆欤�.
霊� 旮堨湹靸來拡氇憪 14.99% 鞁れ 靻岇湢甓� 彀嫧攴滌爼鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟.
彀嫧鞛勱硠臧� 氤€瓴�: 2025雲� 7鞗� 1鞚�, Redmile鞚€ 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办潣鈥滌禍雽€ 牍勳湪鈥濎潉 9.99%鞐愳劀 14.99%搿� 靸來枼臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�, 鞚措姅 61鞚� 頉勳棎氚滍毃霅╇媹雼�. 鞚措ゼ韱淀暣攴鸽９鞚€ 於旉皜鞗岆煱韸鸽ゼ頄夓偓頃橁碃靸堧鞖� 14.99% 頃滊弰鞐� 鞝戧芳頃� 靾� 鞛堨溂雮� 13(d) 臁绊暛頃滊弰電� 齑堦臣頃橃 鞎婌姷雼堧嫟.
鞛愱笀於滌矘: Redmile鞚� 甏€毽晿電� 鞐煬靷 韴瀽韼€霌滌潣鞖挫爠鞛愲掣(鞕鸽秬鞛愱笀臁半嫭鞐嗢潓).
鞐偓鞝� 氚瓣步: 鞚措姅 2018雲勳棎鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 歆€攵� 氚� 歃濌秾甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤€頇旊ゼ氚橃榿頃╇媹雼�.

Propri茅t茅 b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social ordinaire en circulation de FATE (114 633 022 actions au 6 mai 2025).
D茅tail des principaux d茅tenteurs : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir de vote et de disposition partag茅 ; aucune personne d茅clarant n鈥檃 de pouvoir exclusif.
Warrants et actions privil茅gi茅es : 鈥� Warrants pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) ainsi que des actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
Les deux instruments sont soumis 脿 des m茅canismes de blocage de propri茅t茅 b茅n茅ficiaire 脿 14,99 %.
Changement du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 Pourcentage Maximum 禄 sous le m茅canisme de blocage de propri茅t茅 b茅n茅ficiaire des warrants de 9,99 % 脿 14,99 % (effectif 61 jours plus tard). Cela permet au groupe d鈥檈xercer des warrants suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la Section 13(d).
Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position et de la composition des titres de Redmile (ordinaires, warrants, privil茅gi茅es, options, RSU).

骋别蝉补尘迟苍耻迟锄苍颈别脽别谤-贰颈驳别苍迟耻尘: 17.941.579 Stammaktien (direkt und als gehalten betrachtet), was 14,9 % des ausstehenden Stammkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
Details zu Hauptanteilseignern: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen geteilter Stimm- und Verf眉gungsgewalt; keine meldepflichtige Person hat Alleinmacht.
Warrants & Vorzugsaktien: 鈥� Vorgezahlte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, konvertierbar 1 zu 5 in bis zu 810.065 Aktien (RedCo II) sowie weitere Vorzugsaktien in anderen Redmile-Fonds.
Beide Instrumente unterliegen 14,99 % Nutznie脽er-Eigentums-Blockern.
脛nderung der Blockierschwelle: Am 1. Juli 2025 entschied Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant-Nutznie脽er-Eigentums-Blocker von 9,99 % auf 14,99 % anzuheben (wirksam 61 Tage sp盲ter). Dies erm枚glicht der Gruppe, zus盲tzliche Warrants auszu眉ben und sich der neuen 14,99 %-Grenze zu n盲hern, ohne die Sektion 13(d)-Grenzen zu 眉berschreiten.
Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglich 2018 eingereichten 13D, die die Entwicklung von Redmiles Position und Wertpapiermix (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs) widerspiegelt.

07/03/2025 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 3, 2025

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39138		84-2984849
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 Bridge Pkwy Suite #102

Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)	(Trading Symbol)	(Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share	JSPR	The Nasdaq Stock Market LLC
Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00	JSPRW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On July 3, 2025, Jasper Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 12,014,527 shares of the Company’s voting common stock, or approximately 80% of the 15,022,122 shares of the Company’s voting common stock issued and outstanding as of May 9, 2025, the record date for the Annual Meeting, were represented virtually or by proxy.

At the Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 19, 2025.

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

Proposal No. 1: To elect three Class I directors to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified.

Director Nominee	Votes For	Votes Withheld	Broker Non-Votes
Kurt von Emster	8,467,774	186,265	3,360,488
Scott Brun, M.D.	8,612,491	41,548	3,360,488
Vishal Kapoor	8,567,506	86,533	3,360,488

Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2025.

Votes For		Votes Against		Abstentions
11,992,658		18,646		3,223

Proposal No. 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers.

Votes For		Votes Against		Abstentions		Broker Non-Votes
8,108,299		536,022		9,718		3,360,488

Proposal No. 4: To approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers.

Every One Year		Every Two Years		Every Three Years		Abstentions		Broker Non-Votes
8,580,886		5,444		29,171		38,538		3,360,488

In light of the Company’s stockholders voting on an advisory basis to hold future advisory votes on the compensation of the Company’s named executive officers every one year, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JASPER THERAPEUTICS, INC.

Date: July 3, 2025	By:	/s/ Herb Cross
		Name:	Herb Cross
		Title:	Chief Financial Officer

Source:

AG真人官方